The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Pfizer, one of the world’s largest pharmaceutical companies, has announced that David Lepoittevin will be its new country manager for Belgium and Luxembourg.

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total pay increase, according (PDF) to a securities filing.

Pfizer closed at $25.60, slipping 0.43% in the latest session, outperforming broader market losses. While the S&P 500 dropped ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

The global mast cell tumor treatment market is on a strong growth trajectory, with market projections estimating a valuation of USD 7,836.4 million by 2034. This reflects a steady CAGR of 3.4% from ...

Pfizer is ranked third among the best pharma stocks to buy according to hedge funds. The company boasts a strong oncology ...

She believed the industry may not underperform this year ... beating its benchmark by 218 percentage points (see more details ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...